Loading
NASDAQHealthcareBiotechnology
Latest quote
$2.54
+$0.01 · +0.40%
Kiora Pharmaceuticals, Inc., a specialty pharmaceutical firm operating at the clinical stage, is dedicated to the creation and commercialization of treatments for various ophthalmic conditions across the United States. Its flagship therapeutic candidate, KIO-301, is a groundbreaking small molecule undergoing Phase 1 clinical trials. This innovative "photoswitch" aims to revitalize vision in individuals suffering from both inherited and age-related forms of retinal degeneration. The company's pipeline also includes KIO-101, an eye drop currently in Phase 2 trials for addressing the ocular manifestations of rheumatoid arthritis, as well as non-infectious posterior uveitis. Furthermore, Kiora is advancing KIO-201, another eye drop, which is in Phase 3 clinical trials, designed to facilitate corneal wound healing following PRK surgery. Established in 1998, the company adopted its current name in November 2021, having previously operated as Eyegate Pharmaceuticals, Inc. Kiora Pharmaceuticals maintains its corporate headquarters in Salt Lake City, Utah.
Latest quote
$2.54
+$0.01 · +0.40%
After-hours
$2.55
+$0.01 · +0.39%
Oct 9, 4:00 PM ET
Regular session · ET · Market data may be delayed.
Kiora Pharmaceuticals, Inc., a specialty pharmaceutical firm operating at the clinical stage, is dedicated to the creation and commercialization of treatments for various ophthalmic conditions across the United States. Its flagship therapeutic candidate, KIO-301, is a groundbreaking small molecule undergoing Phase 1 clinical trials. This innovative "photoswitch" aims to revitalize vision in individuals suffering from both inherited and age-related forms of retinal degeneration. The company's pipeline also includes KIO-101, an eye drop currently in Phase 2 trials for addressing the ocular manifestations of rheumatoid arthritis, as well as non-infectious posterior uveitis. Furthermore, Kiora is advancing KIO-201, another eye drop, which is in Phase 3 clinical trials, designed to facilitate corneal wound healing following PRK surgery. Established in 1998, the company adopted its current name in November 2021, having previously operated as Eyegate Pharmaceuticals, Inc. Kiora Pharmaceuticals maintains its corporate headquarters in Salt Lake City, Utah.
Day range
Current $2.54
52-week range
Current $2.54
Regular session · ET · Market data may be delayed.
GoAI Score
Sell
Valuation
33
Expensive
Sentiment
47
Mixed
Risk
46
Elevated Risk
Momentum
44
Neutral
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
Kiora Pharmaceuticals, Inc., a specialty pharmaceutical firm operating at the clinical stage, is dedicated to the creation and commercialization of treatments for various ophthalmic conditions across the United States. Its flagship therapeutic candidate, KIO-301, is a groundbreaking small molecule undergoing Phase 1 clinical trials. This innovative "photoswitch" aims to revitalize vision in individuals suffering from both inherited and age-related forms of retinal degeneration. The company's pipeline also includes KIO-101, an eye drop currently in Phase 2 trials for addressing the ocular manifestations of rheumatoid arthritis, as well as non-infectious posterior uveitis. Furthermore, Kiora is advancing KIO-201, another eye drop, which is in Phase 3 clinical trials, designed to facilitate corneal wound healing following PRK surgery. Established in 1998, the company adopted its current name in November 2021, having previously operated as Eyegate Pharmaceuticals, Inc. Kiora Pharmaceuticals maintains its corporate headquarters in Salt Lake City, Utah.
Day range
Current $2.54
52-week range
Current $2.54
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | — | 16M USD | — | — | — |
| Cost of goods sold | 24.8K USD | — | — | — | — |
| Gross profit | −24.8K USD | 16M USD | — | — | — |
| Research and development | 10.78M USD | 4.9M USD | 4.03M USD | 3.45M USD | 5.35M USD |
| Selling, general, and administrative | 5.75M USD | 5.54M USD | 4.66M USD | 8.28M USD | 5.32M USD |
| Operating expenses | 9.43M USD | 11.49M USD | 12.59M USD | 12.31M USD | 14.24M USD |
| Interest income | 894K USD | 1.25M USD | 173.99K USD | 56.89K USD | 1.14K USD |
| Interest expense | 19.96K USD | 21.45K USD | 11.13K USD | 8.6K USD | 6.85K USD |
| Depreciation and amortization | 24.8K USD | 19.21K USD | 51.8K USD | 41.61K USD | 45.3K USD |
| Operating income | −9.46M USD | 4.51M USD | −12.59M USD | −12.31M USD | −14.24M USD |
| Net income | −10.84M USD | 3.59M USD | −12.51M USD | −13.58M USD | −13.77M USD |
Company facts updated Oct 9, 2026.
Recent quarterly results
Recent quarterly results
| Action | Effective date | Details | Record date | Payment date |
|---|---|---|---|---|
Stock split | Jun 11, 2024 | 1:9 | — | — |
Stock split | Sep 27, 2022 | 1:40 | — | — |
Stock split | Aug 30, 2019 | 1:15 | — | — |
Effective Jun 11, 2024
1:9
Effective Sep 27, 2022
1:40
Effective Aug 30, 2019
1:15
Funds reporting this stock among their holdings, ordered by reported position size.
Vanguard Extended Market ETFVXF55.15K0.00%95.4B USD0.05%$235+0.80%
U.S. Vector Equity Portfolio ETF Class SharesDXUV9.93K0.00%6.17B USD0.26%$68.28+0.25%
Dimensional - US Core Equity 2 ETFDFAC8.88K0.00%88.2B USD0.21%$45.33+0.49%
U.S. Core Equity 1 Portfolio ETF Class SharesDCOR3.98K0.00%45.38B USD0.17%$84.44+0.44%
Dimensional - US Sustainability Core 1 ETFDFSU3.11K0.00%2.38B USD0.15%$48.11+0.48%Vanguard Extended Market ETFVXFU.S. Vector Equity Portfolio ETF Class SharesDXUVDimensional - US Core Equity 2 ETFDFACU.S. Core Equity 1 Portfolio ETF Class SharesDCORDimensional - US Sustainability Core 1 ETFDFSUAI-generated and delayed market data for informational and educational purposes only. Not investment advice.